SENSEX NIFTY
Jan 02, 2013, 09.15 AM IST | Source: PTI

Aurobindo gets USFDA nod for anti-migraine tablets

Drug maker Aurobindo Pharma Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Drug maker Aurobindo Pharma Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Also read: FMCG, pharma stocks hog limelight as defensive bets

The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said.

Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co's Maxalt Tablets of equivalent dose and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

The annual sale of the product is approximately USD 300 million for 12 months ending March 2012 according to IMS data, the release said.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.

Aurobindo now has a total of 171 abbreviated new drug application (ANDA) approvals (146 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA, according to Aurobindo.

Aurobindo scrip is traded at Rs 193.25 apiece on BSE in the afternoon trade.

Aurobindo Pharm stock price

On September 19, 2014, Aurobindo Pharma closed at Rs 867.60, down Rs 16.2, or 1.83 percent. The 52-week high of the share was Rs 908.00 and the 52-week low was Rs 178.00.


The company's trailing 12-month (TTM) EPS was at Rs 48.78 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 17.79. The latest book value of the company is Rs 137.67 per share. At current value, the price-to-book value of the company is 6.30.

READ MORE ON  Aurobindo Pharma, USFDA, migraine, FDA
Set email alert for

ADS BY GOOGLE

video of the day

Retail buyers, MFs are back; midcaps hold promise: Ambit

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.